June 3, 2022New England Journal of MedicineOpen Access

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

View Full Paper

Ask AI

Bookmark

Abstract

In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jänne et al. (2022) studied this question.

synapsesocial.com/papers/69d96e6234ded318bb684331 https://doi.org/10.1056/nejmoa2204619

View Full Paper

Ask AI

Bookmark

Abstract

In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

Abstract

Discussion

Cite This Study

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

Abstract

Discussion

Cite This Study

Also Consider

Also Consider